Seres Therapeutics, Inc. - 8-K Filing
Seres Therapeutics, Inc. amended its asset purchase agreement with Société des Produits Nestlé S.A., receiving $25 million in two installments to terminate future milestone payments tied to product sales thresholds of $400 million and $750 million. The company also modified its lease at 101 CambridgePark Drive, reducing the leased space by ~55%, deferring rent for eight months, and paying a total of $9.7 million in termination fees. (Items: 1.01 Entry into a Material Definitive Agreement, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $MCRB